MRX

Class [005]
Pharmaceutical preparations for the treatment of depression, cancer, bacterial infections, namely bacterial intestinal infections and Clostridium difficile infections, vaccine adjuvancy, lung injury and asthma; pharmaceutical preparations for the treatment of autoimmune diseases and inflammatory diseases, namely inflammatory bowel diseases and inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of neurological diseases and neurodegenerative diseases, namely Parkinson's, Alzheimer's, Huntington's Disease and cerebral palsy; pharmaceutical preparations for the treatment of central nervous system disorders, namely autism, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases; pharmaceutical preparations for the treatment of brain injury; pharmaceutical preparations for the treatment of autoimmune disorders of the central nervous system and inflammatory disorders of the central nervous system; pharmaceutical preparations for the treatment of diarrhoea, constipation and sensory hypersensitivity; and pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations as live biotherapeutics for the treatment of depression, cancer, bacterial infections, namely bacterial intestinal infections and Clostridium difficile infections, vaccine adjuvancy, lung injury and asthma; pharmaceutical preparations as live biotherapeutics for the treatment of autoimmune diseases and inflammatory diseases, namely inflammatory bowel diseases and inflammatory connective tissue diseases; pharmaceutical preparations as live biotherapeutics for the treatment of neurological diseases and neurodegenerative diseases, namely Parkinson's, Alzheimer's, Huntington's Disease and cerebral palsy; pharmaceutical preparations as live biotherapeutics for the treatment of central nervous system disorders, namely autism, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases; pharmaceutical preparations as live biotherapeutics for the treatment of brain injury; pharmaceutical preparations as live biotherapeutics for the treatment of autoimmune disorders of the central nervous system and inflammatory disorders of the central nervous system; pharmaceutical preparations as live biotherapeutics for the treatment of diarrhoea, constipation and sensory hypersensitivity; and pharmaceutical preparations as live biotherapeutics for the treatment of gastro-intestinal diseases; live biotherapeutic bacterial formulations for the treatment of depression, cancer, bacterial infections, namely bacterial intestinal infections and Clostridium difficile infections, vaccine adjuvancy, lung injury and asthma; live biotherapeutic bacterial formulations for the treatment of autoimmune diseases and inflammatory diseases, namely inflammatory bowel diseases and inflammatory connective tissue diseases; live biotherapeutic bacterial formulations for the treatment of neurological diseases and neurodegenerative diseases, namely Parkinson's, Alzheimer's, Huntington's Disease and cerebral palsy; live biotherapeutic bacterial formulations for the treatment of central nervous system disorders, namely autism, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases; live biotherapeutic bacterial formulations for the treatment of brain injury; live biotherapeutic bacterial formulations for the treatment of autoimmune disorders of the central nervous system and inflammatory disorders of the central nervous system; live biotherapeutic bacterial formulations for the treatment of diarrhoea, constipation and sensory hypersensitivity; and live biotherapeutic bacterial formulations for the treatment of gastro-intestinal diseases; preparations of microorganisms for the treatment of depression, cancer, bacterial infections, namely bacterial intestinal infections and Clostridium difficile infections, vaccine adjuvancy, lung injury and asthma; preparations of microorganisms for the treatment of autoimmune diseases and inflammatory diseases, namely inflammatory bowel diseases and inflammatory connective tissue diseases; preparations of microorganisms for the treatment of neurological diseases and neurodegenerative diseases, namely Parkinson's, Alzheimer's, Huntington's Disease and cerebral palsy; preparations of microorganisms for the treatment of central nervous system disorders, namely autism, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases; preparations of microorganisms for the treatment of brain injury; preparations of microorganisms for the treatment of autoimmune disorders of the central nervous system and inflammatory disorders of the central nervous system; preparations of microorganisms for the treatment of diarrhoea, constipation and sensory hypersensitivity; and preparations of microorganisms for the treatment of gastro-intestinal diseases